Aggregation of Prion Protein with Insertion Mutations is Proportional to the Number of Inserts

Overview

Journal Biochem J

Specialty Biochemistry

Date 2006 Dec 26

PMID 17187581

Citations 15

Authors

Shuiliang Yu

Shaoman Yin

Chaoyang Li

Poki Wong

Binggong Chang

Fan Xiao

Shin-Chung Kang

Huimin Yan

Gengfu Xiao

Po Tien

Man-Sun Sy

Affiliations

Soon will be listed here.

Abstract

Mutation in the prion gene, PRNP, accounts for approx. 10-15% of human prion diseases. However, little is known about the mechanisms by which a mutant prion protein (PrP) causes disease. We compared the biochemical properties of a wild-type human prion protein, rPrP(C) (recombinant wild-type PrP), which has five octapeptide-repeats, with two recombinant human prion proteins with insertion mutations, one with three more octapeptide repeats, rPrP(8OR), and the other with five more octapeptide repeats, rPrP(10OR). We found that the insertion mutant proteins are more prone to aggregate, and the degree and kinetics of aggregation are proportional to the number of inserts. The octapeptide-repeat and alpha-helix 1 regions are important in aggregate formation, because aggregation is inhibited with monoclonal antibodies that are specific for epitopes in these regions. We also showed that a small amount of mutant protein could enhance the formation of mixed aggregates that are composed of mutant protein and wild-type rPrP(C). Accordingly, rPrP(10OR) is also more efficient in promoting the aggregation of rPrP(C) than rPrP(8OR). These findings provide a biochemical explanation for the clinical observations that the severity of the disease in patients with insertion mutations is proportional to the number of inserts, and thus have implications for the pathogenesis of inherited human prion disease.

Citing Articles

Big versus small: The impact of aggregate size in disease.

Hnath B, Chen J, Reynolds J, Choi E, Wang J, Zhang D Protein Sci. 2023; 32(7):e4686.

PMID: 37243896 PMC: 10273386. DOI: 10.1002/pro.4686.

Activation of Src family kinase ameliorates secretory trafficking in mutant prion protein cells.

Restelli E, Capone V, Pozzoli M, Ortolan D, Quaglio E, Corbelli A J Biol Chem. 2021; 296:100490.

PMID: 33662396 PMC: 8059059. DOI: 10.1016/j.jbc.2021.100490.

N-Terminal Regions of Prion Protein: Functions and Roles in Prion Diseases.

Hara H, Sakaguchi S Int J Mol Sci. 2020; 21(17).

PMID: 32872280 PMC: 7504422. DOI: 10.3390/ijms21176233.

Instability of the octarepeat region of the human prion protein gene.

Li B, Qing L, Yan J, Kong Q PLoS One. 2011; 6(10):e26635.

PMID: 22028931 PMC: 3197570. DOI: 10.1371/journal.pone.0026635.

A multistage pathway for human prion protein aggregation in vitro: from multimeric seeds to β-oligomers and nonfibrillar structures.

Cho K, Huang Y, Yu S, Yin S, Plomp M, Qiu S J Am Chem Soc. 2011; 133(22):8586-93.

PMID: 21534611 PMC: 4505822. DOI: 10.1021/ja1117446.

References

Bocharova O, Breydo L, Parfenov A, Salnikov V, Baskakov I . In vitro conversion of full-length mammalian prion protein produces amyloid form with physical properties of PrP(Sc). J Mol Biol. 2005; 346(2):645-59. DOI: 10.1016/j.jmb.2004.11.068. View

Mead S . Prion disease genetics. Eur J Hum Genet. 2006; 14(3):273-81. DOI: 10.1038/sj.ejhg.5201544. View

Moore R, Herzog C, Errett J, Kocisko D, Arnold K, Hayes S . Octapeptide repeat insertions increase the rate of protease-resistant prion protein formation. Protein Sci. 2006; 15(3):609-19. PMC: 2249780. DOI: 10.1110/ps.051822606. View

Jones E, Surewicz K, Surewicz W . Role of N-terminal familial mutations in prion protein fibrillization and prion amyloid propagation in vitro. J Biol Chem. 2006; 281(12):8190-6. DOI: 10.1074/jbc.M513417200. View

Luhrs T, Zahn R, Wuthrich K . Amyloid formation by recombinant full-length prion proteins in phospholipid bicelle solutions. J Mol Biol. 2006; 357(3):833-41. DOI: 10.1016/j.jmb.2006.01.016. View

Yin S, Yu S, Li C, Wong P, Chang B, Xiao F . Prion proteins with insertion mutations have altered N-terminal conformation and increased ligand binding activity and are more susceptible to oxidative attack. J Biol Chem. 2006; 281(16):10698-705. DOI: 10.1074/jbc.M511819200. View

Ricchelli F, Buggio R, Drago D, Salmona M, Forloni G, Negro A . Aggregation/fibrillogenesis of recombinant human prion protein and Gerstmann-Sträussler-Scheinker disease peptides in the presence of metal ions. Biochemistry. 2006; 45(21):6724-32. DOI: 10.1021/bi0601454. View

Wadsworth J, Joiner S, Linehan J, Cooper S, Powell C, Mallinson G . Phenotypic heterogeneity in inherited prion disease (P102L) is associated with differential propagation of protease-resistant wild-type and mutant prion protein. Brain. 2006; 129(Pt 6):1557-69. DOI: 10.1093/brain/awl076. View

Pankiewicz J, Prelli F, Sy M, Kascsak R, Kascsak R, Spinner D . Clearance and prevention of prion infection in cell culture by anti-PrP antibodies. Eur J Neurosci. 2006; 23(10):2635-47. PMC: 1779824. DOI: 10.1111/j.1460-9568.2006.04805.x. View

10.

Lewis P, Tattum M, Jones S, Bhelt D, Batchelor M, Clarke A . Codon 129 polymorphism of the human prion protein influences the kinetics of amyloid formation. J Gen Virol. 2006; 87(Pt 8):2443-2449. DOI: 10.1099/vir.0.81630-0. View

11.

Tsiroulnikov K, Rezaei H, Dalgalarrondo M, Chobert J, Grosclaude J, Haertle T . Cu(II) induces small-size aggregates with amyloid characteristics in two alleles of recombinant ovine prion proteins. Biochim Biophys Acta. 2006; 1764(7):1218-26. DOI: 10.1016/j.bbapap.2006.04.013. View

12.

Tahiri-Alaoui A, James W . Rapid formation of amyloid from alpha-monomeric recombinant human PrP in vitro. Protein Sci. 2005; 14(4):942-7. PMC: 2253435. DOI: 10.1110/ps.041000905. View

13.

Cohen F . Protein misfolding and prion diseases. J Mol Biol. 1999; 293(2):313-20. DOI: 10.1006/jmbi.1999.2990. View

14.

Swietnicki W, Morillas M, Chen S, Gambetti P, Surewicz W . Aggregation and fibrillization of the recombinant human prion protein huPrP90-231. Biochemistry. 2000; 39(2):424-31. DOI: 10.1021/bi991967m. View

15.

Baskakov I, Aagaard C, Mehlhorn I, Wille H, Groth D, Baldwin M . Self-assembly of recombinant prion protein of 106 residues. Biochemistry. 2000; 39(10):2792-804. DOI: 10.1021/bi9923353. View

16.

Qin K, Yang D, Yang Y, Chishti M, Meng L, Kretzschmar H . Copper(II)-induced conformational changes and protease resistance in recombinant and cellular PrP. Effect of protein age and deamidation. J Biol Chem. 2000; 275(25):19121-31. DOI: 10.1074/jbc.275.25.19121. View

17.

Li R, Liu T, Wong B, Pan T, Morillas M, Swietnicki W . Identification of an epitope in the C terminus of normal prion protein whose expression is modulated by binding events in the N terminus. J Mol Biol. 2000; 301(3):567-73. DOI: 10.1006/jmbi.2000.3986. View

18.

Cordeiro Y, Machado F, Juliano L, Juliano M, Brentani R, Foguel D . DNA converts cellular prion protein into the beta-sheet conformation and inhibits prion peptide aggregation. J Biol Chem. 2001; 276(52):49400-9. DOI: 10.1074/jbc.M106707200. View

19.

Baskakov I, Legname G, Baldwin M, Prusiner S, Cohen F . Pathway complexity of prion protein assembly into amyloid. J Biol Chem. 2002; 277(24):21140-8. DOI: 10.1074/jbc.M111402200. View

20.

Kovacs G, Trabattoni G, Hainfellner J, Ironside J, Knight R, Budka H . Mutations of the prion protein gene phenotypic spectrum. J Neurol. 2002; 249(11):1567-82. DOI: 10.1007/s00415-002-0896-9. View